Primary central nervous system lymphoma
Conditions
Interventions
Experimental group:Zanubrutinib was administered as maintenance therapy at a dose of 160 mg twice daily for 2 years.
Control group:Only regular follow-up, no maintenance treatment with zanubrutinib or other anti-tumor drugs.
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-80 years; 2.Pathologically confirmed PCNSL; 3.No evidence of systemic lymphoma; 4.HIV-Ab negative; 5.Achieved remission (complete remission and partial remission) after first-line induction or consolidation therapy; 6.Less than or equal to 3 months after the last dose of systemic therapy including chemotherapy or autologous hematopoietic stem cell transplantation; 7.Adequate organ and bone marrow function, without severe hematopoietic abnormalities, heart, lung, liver, kidney, thyroid dysfunction and immune deficiencies (without receiving blood transfusion, granulocyte colony-stimulating factor or other relevant medical support within 14 days prior to the use of the study drug); 8.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Multiple factors affecting oral administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 2.Hypersensitivity to the study drug or excipients; 3.Patients with other tumors combined; 4.Patients with concurrent active infection; 5.Presence of active bleeding; 6.Other conditions which are unsuitable for inclusion in the study at the discretion of the investigator; 7.Pregnant Or lactating Women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug safety in subjects;2-year overall survival; | — |
Countries
China
Contacts
Public ContactYan Zhang
Peking Union Medical College Hospital
Outcome results
None listed